Environmental

ERAS appears to have limited direct environmental exposure as a biotechnology company, which reduces peer-relative emissions and resource-intensity risk versus manufacturing-heavy peers.

The provided metrics show no R&D-to-revenue intensity, limiting evidence of environmental process burden, but this also leaves peer comparison constrained versus better-disclosed biotech peers.

Low leverage and near-zero net debt reduce financing pressure for capital-intensive environmental compliance, though this is less material than operational footprint in the sector.

Absent disclosed environmental targets, emissions data, or climate-risk controls in the provided information, ERAS cannot be assessed as a leader relative to more transparent peers.

Social

As a biotech issuer, ERAS likely faces lower workforce-safety and supply-chain labor complexity than industrial peers, supporting a modest peer-relative social profile.

The absence of stock-based compensation intensity in the provided metrics suggests less dilution-linked employee incentive pressure, but peer comparison remains limited without broader disclosure.

No human-capital, clinical-trial, or patient-safety metrics are provided, so social positioning cannot be judged above peers with stronger disclosure and governance around trial conduct.

Limited disclosed social data constrains confidence, leaving ERAS broadly in line with smaller biotech peers rather than clearly advantaged on stakeholder management.

Governance

The low debt-to-equity ratio and negative net debt-to-EBITDA indicate conservative balance-sheet governance, which is favorable versus more levered peers.

However, the provided metrics do not address board independence, executive alignment, audit quality, or shareholder-rights protections, which are central governance differentiators.

Zero stock-based compensation intensity may indicate restrained equity dilution, but it also prevents assessment of whether pay practices are more disciplined than peers.

Overall governance appears adequate but not demonstrably superior, because the available data show balance-sheet prudence without the disclosure depth seen in stronger peers.

Overall Score

ERAS screens as a broadly average ESG profile versus peers, with modest balance-sheet discipline offset by limited disclosure across the most material ESG dimensions.

Score Driver: Limited ESG Disclosure Prevents ERAS From Demonstrating A Clear Peer-Relative Advantage Despite Some Favorable Capital-Structure Signals.